Matsuyama Satoshi, Otsubo Tempei, Nomoto Keisuke, Higa Shingo, Takashio Osamu
Medical Affairs, Viatris Pharmaceuticals Japan Inc., Tokyo, Japan.
Department of Psychosomatic and Psychiatric Medicine, Tokyo Women's Medical University Adachi Medical Center, Tokyo, Japan.
Neuropsychiatr Dis Treat. 2024 Jun 26;20:1355-1366. doi: 10.2147/NDT.S456272. eCollection 2024.
Generalized anxiety disorder (GAD) is among the most prevalent and highly disabling mental health conditions that negatively impacts patient's quality of life (QOL) and disrupts activities of daily living. However, the recognition of GAD is difficult due to substantial overlap with other mental disorders. The purpose of this study was to estimate the prevalence of GAD, assess QOL of probable GAD patients in Japan, and gain insights on the status of visiting medical institutions as well as their recognition/awareness of the disorder.
We conducted a web-based cross-sectional survey of 20,009 participants using a questionnaire with approximately 30 single/multiple choice or open-ended questions in Japanese.
Overall prevalence of GAD based on Generalized Anxiety Disorder 7-item (GAD-7) cutoff score of ≥10 and questionnaires developed with reference to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria was 7.6% (n=1530) and 6.0% (n=1197), respectively. The degree of coincidence between GAD diagnosis by DSM-5 criteria and GAD-7 scores was moderate (Cohen's Kappa=0.47, <0.01). Younger people reported a substantially higher prevalence of GAD compared to older. QOL scores assessed using EuroQol 5 dimensions 5-level and EuroQol Visual Analog Scale were substantially lower in probable GAD patients than those with GAD-7<10. Anxiety/depression and pain/discomfort were the most prevalent issues and depression was the most reported comorbidity for the probable GAD patients. Probable GAD patients "currently visiting medical institutions" for anxiety or other mental issues were 27.6% (422/1530); a majority had seen specialists. Most of the probable GAD patients had never heard of the disease.
We found higher prevalence of GAD and lower QOL of probable GAD patients in Japan. There is a need for creating awareness about GAD among the general population and developing clinical guidelines on GAD in Japan so that physicians can educate their patients.
广泛性焦虑障碍(GAD)是最常见且极具致残性的心理健康状况之一,会对患者的生活质量(QOL)产生负面影响,并扰乱日常生活活动。然而,由于与其他精神障碍存在大量重叠,GAD的识别较为困难。本研究的目的是估计GAD的患病率,评估日本可能患有GAD的患者的生活质量,并深入了解就诊医疗机构的状况以及他们对该疾病的认识/知晓情况。
我们使用一份包含约30个单项/多项选择题或开放式问题的日语问卷,对20,009名参与者进行了基于网络的横断面调查。
根据广泛性焦虑障碍7项(GAD-7)截断分数≥10以及参照《精神疾病诊断与统计手册》第五版(DSM-5)标准编制的问卷,GAD的总体患病率分别为7.6%(n = 1530)和6.0%(n = 1197)。DSM-5标准诊断的GAD与GAD-7分数之间的符合程度为中等(科恩kappa系数 = 0.47,<0.01)。年轻人报告的GAD患病率明显高于老年人。使用欧洲五维度健康量表(EuroQol 5 dimensions 5-level)和欧洲视觉模拟量表(EuroQol Visual Analog Scale)评估的生活质量分数,可能患有GAD的患者明显低于GAD-7分数<10的患者。焦虑/抑郁和疼痛/不适是最普遍的问题,抑郁是可能患有GAD的患者中报告最多的共病。因焦虑或其他精神问题“目前正在就诊医疗机构”的可能患有GAD的患者占27.6%(422/1530);大多数人看过专科医生。大多数可能患有GAD的患者从未听说过这种疾病。
我们发现日本GAD的患病率较高,可能患有GAD的患者的生活质量较低。有必要在普通人群中提高对GAD的认识,并在日本制定关于GAD的临床指南,以便医生能够教育他们的患者。